48 results about "Haemorrhagic disorders" patented technology

An antimicrobial barrier comprising a structure including a chitosan biomaterial. The antimicrobial barrier can be used, e.g., (i) stanch, seal, or stabilize a site of tissue injury, tissue trauma, or tissue access; or (ii) form an anti-microbial barrier; or (iii) form an antiviral patch; or (iv) intervene in a bleeding disorder; or (v) release a therapeutic agent; or (vi) treat a mucosal surface; or (vii) combinations thereof. The structure of the antimicrobial barrier may be densified by compression.

Disclosed are methods for treating bleeding disorders, such as hemophilia, in subjects in need thereof by administering an antibody that specifically binds CD73. The methods reduce production of adenosine, increase platelet activation and / or enhance the level of coagulation on the platelet surface to reduce and / or stop bleeding. In some embodiments, the methods can further include co-administering Factor VIII to treat the bleeding disorder.

The invention concerns novel coagulation factor VII variants, wherein the Leu residue in position 305 or the Phe residue in position 374 of SEQ ID NO 1 has been replaced by another amino acid residue which can be encoded by nucleic acid constructs and, optionally, wherein at least one other amino acid residue in the remaining positions in the protease domain has been replaced by another amino acid residue which can be encoded by nucleic acid constructs;with the proviso that the variant is not FVII(Ala305).The invention further concerns nucleic acids encoding the Factor VII variants; vectors and cells comprising the nucleic acid; methods for producing the variants; pharmaceutical compositions comprising a Factor VII variant wherein the Leu residue in position 305 or the Phe residue in position 374 of SEQ ID NO 1 has been replaced by another amino acid residue which can be encoded by nucleic acid constructs and, optionally, wherein at least one other amino acid residue in the remaining positions in the protease domain has been replaced by another amino acid residue which can be encoded by nucleic acid constructs; use of the variants for producing a medicament for treatment or prophylaxis of bleeding disorders or enhancement of the coagulation system; and methods of treatment.

The present invention relates to recombinant blood coagulation factor IX (rFIX) mutants having improved FIX clotting activity. Three full length FIX proteins with combinations of mutations of amino acids important for functional activity of FIX and FIX wild type were cloned and expressed in HEK 293 cells. The proteins were tested by an activated partial thromboplastin time (aPTT) assays in FIX-depleted plasma. Two mutant proteins had increased specific FIX activity. Furthermore, a pre-activated FIX protein had an increased activity in FIX-depleted plasma. Therefore these FIX mutants can be used for the treatment of FIX associated bleeding disorders.

One kind blood samples detection method using magnetic beads, completed with the following steps: (1) Get fresh clinical samples; (2)Put these specimen on coagulation analyzer, use magnetic beads and special adjustment reagents aiming at the whole blood specimens, measure four coagulations: Activated partial thromboplastin time (APTT), Prothrombin time (PT), Prothrombin time (TT), Fibrinogen (FIB). The advantages of this invention are: 1.The method is simple, time-saving and easy to technical staff. 2. Reduce costs and save centrifuges and other equipment, reduce errors; 3. It is efficient and suitable for the battlefield, natural disasters and remote mountainous areas, medical teams. Particularly, it's suitable for hemorrhagic diseases and natural disasters (such as hemophilia, etc.). 4. Save specimen volume. 5. Reflect the level of specimens of blood coagulation preciously and accurately.

The present invention provides methods of administering a clotting factor by a fixed dosing regimen; methods of reducing, ameliorating, or preventing one or more symptoms of a bleeding disease or disorder; and a kit comprising a dotting factor useful for a fixed dosing regimen. While plasma-derived and recombinant clotting factor products allow hemophilia patients to live longer and healthier, hemophilia still remains one of the most costly and complex conditions to manage.

The present invention is directed to liquid, aqueous pharmaceutical compositions containing Factor VII polypeptides, and methods for preparing and using such compositions, as well as vials containing such compositions, and the use of such compositions in the treatment of a Factor VII-responsive syndrome, e.g., bleeding disorders, including those caused by clotting Factor deficiencies (e.g. haemophilia A, haemophilia B, coagulation Factor VII deficiency); by thrombocytopenia or von Willebrand's disease, or by clotting Factor inhibitors, and intra cerebral haemorrhage, or excessive bleeding from any cause. The preparations may also be administered to patients in association with surgery or other trauma or to patients receiving anticoagulant therapy. More particularly, the invention relates to liquid compositions stabilised against chemical and / or physical degradation. The main embodiment is represented by a liquid, aqueous pharmaceutical composition comprising a Factor VII polypeptide (i); a buffering agent (ii) suitable for keeping pH in the range of from about 4.0 to about 9.0; at least one metal-containing agent (iii), wherein said metal is selected from the group consisting of first transition series metals of oxidation state +II, except zinc, such as chromium, manganese, iron, cobalt, nickel, and copper; and a non-ionic surfactant (iv).

The invention relates to C27 spirostane-type steroidal saponins isolated from Ypsilandra, Trillium and Paris and their preparation method, as well as their application in the preparation of drugs for treating hemorrhagic diseases, and application in the preparation of drugs for treating dysfunctional uterine bleeding, and the preparation of functional daily chemical products and health products. The materials used in a method of the invention are easy to obtain, the method is simple and easily operable, biological experiments of the compound produced show that the compound can induce platelet aggregation activity and hemostatic activity significantly.

The present invention relates to variants of a vitamin K-dependent serine protease of the coagulation cascade, preferably variants of factor IX (F.IX), wherein the variant is characterized in that it has clotting activity in absence of its cofactor. The present invention furthermore relates to the use of these variants for the treatment and / or prophylaxis of bleeding disorders, in particular hemophilia A and / or hemophilia B or hemophilia caused or complicated by inhibitory antibodies to F.VIII. The present invention also relates to further variants of factor IX (F.IX) which have desired properties and can, thus be tailored for respective specific therapeutic applications.

The invention provides a method of treating bleeding disorders in a subject by administration of a preparation enriched for Factor IXa. The Factor IXa can be produced by proteolytically activating recombinantly-produced Factor IX. The invention also provides an improved method for producing Factor IXa from a plasma fraction, which method results in a Factor IXa product containing little or no prekallikrein activity, thus reducing the incidence of undesired side effects in a subject.

The present invention discloses anti-idiotypic antibodies and fragments thereof against inhibitory Factor VIII anti-bodies, said inhibitory antibodies having an affinity for the C2 domain of Factor VIII. The anti-idiotypic antibodies of the present invention are able to completely neutralise in vitro and in an in vivo mouse model the inhibitory activity of FVIII inhibitors. The anti idiotypic antibodies of the present invention can be applied for the prevention, treatment or reduction of bleeding disorders of hemophilia patients with inhibitory antibody against the C2 domain of Factor VIII.

The present invention relates to the use of von Willebrand Factor (VWF) preparations or of a VWF preparation in combination with coagulation Factor VIII (FVIII) for extravascular administration in the therapy and prophylactic treatment of bleeding disorders.

The present invention relates to the conjugation of Factor VII polypeptides with heparosan polymers. The resultant conjugates may be used to deliver Factor VII, for example in the treatment or prevention of bleeding disorder

The present invention relates to a high-activity blood coagulation factor XI mutant Ala570Thr (A570T), nucleotide sequences are shown as SEQ ID NO: 1-4 and an amino acid sequence is shown as SEQ ID NO: 5. A zymogen state is activated into an enzyme with activity to produce resistance of a physiological inhibitor, thus the high-activity blood coagulation factor XI mutant Ala570Thr has very high coagulation activity and stronger catalytic capability on a non-physiological substrate, is applied to treatments of hemorrhagic diseases, and has very good prospects for gene treatment, gene editing andrecombinant protein replacement.

The present disclosure provides protease-activatable procoagulant compounds comprising a procoagulant polypeptide, e.g., a procoagulant peptide and / or clotting factor, and a linker comprising a protease-cleavable substrate (e.g., a synthetic thrombin substrate) and a self-immolative spacer (e.g., p-amino benzyl carbamate). Upon cleavage of the protease-cleavable substrate by a protease (e.g., thrombin), the self-immolative spacer cleaves itself from the procoagulant polypeptide such that the polypeptide is in an underivatized and active form. Also provided are pharmaceutical compositions, methods for treating bleeding disorders using the disclosed compounds, methods of enhancing in vivo efficacy of procoagulant polypeptides, methods of increasing the efficacy of proteolytic cleavage of compounds comprising procoagulant polypeptides, methods of activating procoagulant polypeptides, and methods of releasing a procoagulant polypeptide from a heterologous moiety such as PEG.

Disclosed are methods for treating bleeding disorders, such as hemophilia, in subjects in need thereof by administering an antibody that specifically binds CD73. The methods reduce production of adenosine, increase platelet activation and / or enhance the level of coagulation on the platelet surface to reduce and / or stop bleeding. In some embodiments, the methods can further include co-administering Factor VIII to treat the bleeding disorder.

The present invention relates to methods of treatment by human ADAMTS13 inhibition in circulatory assist device induced haemorrhagic complication such as a bleeding disorder, in particular, bleeding after left ventricular assist device implantation. The present invention further relates to specific monoclonal antibodies inhibiting ADAMTS13 function.

The invention discloses a thrombus and hemorrhagic disease gene diagnosis method. All currently known 156 related genes which directly or indirectly influence blood coagulation can be comprehensivelyand systematically analyzed at a time, and key points can be placed in areas, closely related to diseases, in human genomes to find out pathogenic mutations. Most of gene variations such as point mutation, small fragment and large fragment insertion and deletion, copy number change and the like are widely screened, covered and mutated for genes involved in a blood coagulation factor system, a platelet system, a fibrinolytic system, an endothelial system, an inflammatory system, a metabolic system and an anticoagulation system at a time. Compared with other popular whole-genome sequencing technologies at present, the method is superior to whole-genome sequencing in indexes such as thrombus-related target area coverage, effective data volume, capture efficiency data utilization rate, averagesequencing depth and repetition rate, and can effectively improve the diagnosis rate of thrombotic diseases and hemorrhagic diseases.

The present invention provides methods of administering a clotting factor by a fixed dosing regimen; methods of reducing, ameliorating, or preventing one or more symptoms of a bleeding disease or disorder; and a kit comprising a dotting factor useful for a fixed dosing regimen. While plasma-derived and recombinant clotting factor products allow hemophilia patients to live longer and healthier, hemophilia still remains one of the most costly and complex conditions to manage.

The invention relates to iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and to treat subjects having a Serpinc1-associated disease, e.g., a bleeding disorder, such as a hemophilia.

The transdifferentiation of bone marrow cells (BMCs) into hepatocytes can be used for the development of cellular medicine for degenerative and genetic diseases. Since the liver is the primary site of factor VIII (FVIII) synthesis, the partial replacement of mutated liver cells by healthy cells in hemophilia A (HA) could manage the severity of the bleeding disorder. The use of BMCs could be used as a therapy for the bleeding phenotype of hemophilia A and other related disorders.

The invention relates to aprotinin or application of a mutant, a derivative and an analogue or a combination fragment thereof. The aprotinin is used for preparing a medicine for treating related diseases or symptoms with acquired hemophilia and hemophilia with production of inhibitors. The aprotinin can be used for preparing the medicines for hemorrhagic diseases, especially related medicines forhemophilia with inhibitors, and the prospect is good.

The present invention further relates to specific humanised monoclonal antibodies inhibiting ADAMTS13 function. The present invention relates to methods of treatment by human ADAMTS13 inhibition in circulatory assist device induced haemorrhagic complication such as a bleeding disorder, in particular, bleeding after left ventricular assist device (LVAD) implantation.

The present invention relates to methods of treatment by human ADAMTS13 inhibition in circulatory assist device induced haemorrhagic complication such as a bleeding disorder, in particular, bleeding after left ventricular assist device implantation. The present invention further relates to specific monoclonal antibodies inhibiting ADAMTS13 function.

This invention provides a methods of detecting a bleeding disorder in mammals where the bleeding disorder is characterized by normal fibrinogen binding to ADP-activated platelets, but decreased fibrinogen binding to thrombin-activates platelets.

The invention provides an intelligent prediction model construction method for hemorrhagic diseases. The method comprises the following steps: establishing a database of a mapping relationship betweenfeature information of body hemorrhage explicit information representation and hemorrhagic disease symptom feature information; and establishing a calculation model of the semantic similarity of thefeature information between the body hemorrhage explicit information representation and the hemorrhagic disease pair according to the obtained matching relationship between the body hemorrhage explicit information representation and the hemorrhagic disease symptom feature information representation. According to the method, semantic cognition of the relationship between the feature information ofthe body hemorrhage explicit information representation and the disease is realized through the construction of the intelligent prediction model of the hemorrhagic disease, so that the category of thehemorrhagic disease, the bleeding reason and the possible disease are intelligently predicted or evaluated and diagnosed in an assisted manner.

The invention relates to an internal traditional Chinese medicine composition for treating a hemorrhagic disease of fish and a preparation method of the internal traditional Chinese medicine composition. The internal traditional Chinese medicine composition comprises the following components in parts by weight: 10-20 parts of rhizoma polygoni paleacei, 10-20 parts of gardenia, 10-20 parts of dracocephalum moldavuca linn, 5-20 parts of rhizoma dryopteris crassirhizomae and 10-30 parts of diversecolor cinquefoil. The traditional Chinese medicine composition provided by the invention is scientific in compatibility, simple in process, convenient to use, relatively low in cost, and free of a medicine residue and a toxic or side effect, and can effectively play good roles in prevention and treatment of red muscle type, red-fin and red-operculum type and enteritis intestinal bleeding.

The invention relates to a method for simultaneously detecting five hemorrhagic diseases clinically and a preparation method of a kit. The method is characterized by comprising the following steps: (1) preparing a kit containing fresh mixed plasma, barium sulfate adsorbed plasma and stored serum; and (2) adding a certain amount of plasma of a patient to be detected into each tube of the kit, and respectively detecting activated partial thromboplastin time (APTT) of each tube. The five hemorrhagic diseases are diagnosed in a laboratory according to the comparison condition (correction condition) of the APTT time of the reagent containing tube and the APTT time of the plasma of the patient. And (3) diluting the mixed plasma with different concentrations by using the stored serum and the barium sulfate adsorbed plasma respectively, determining activated partial thromboplastin time (APTT) to obtain standard curves of factors VIII and IX, and quantitatively determining the factors VIII and IX of the patient.